中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats

文献类型：期刊论文

作者Zhao, Congke5,6; Hu, Liqing5; He, Xiangrong6; Li, Lijun6; Yin, Minghui6; Tettey, Abraham Terkpertey6; Wang, Yu4; Shen, Jingshan4; Tang, Siyuan3; Wu, Chunhui2
刊名VASCULAR PHARMACOLOGY
出版日期2022-08-01
卷号145页码:11
关键词Pulmonary hypertension Hypoxia Monocrotaline Anti-inflammatory effects NLRP3 inflammasome Pulmonary artery endothelial cells
ISSN号1537-1891
DOI10.1016/j.vph.2022.107017
通讯作者Wang, Zhen(wangzhen@lglab.ac.cn) ; Li, Xiaohui(xiaohuili@csu.edu.cn)
英文摘要Pulmonary hypertension (PH) is a progressive and life-threatening disease with poor prognosis despite many advances in medical therapy over the past 20 years. Novel therapies which target on the underlying pathology of PH are still urgent to be met. TPN171H is a recently found new compound that exhibits potent pharmacological effects in PH via inhibiting phosphodiesterase type 5 (PDE-5). However, as one icariin derivative, the antiinflammatory effects of TPN171H for treating PH are not clear. The present study was designed to investigate the therapeutical effect of TPN171H against inflammation in PH and reveal the underlying mechanism. Hypoxia and monocrotaline (MCT)-induced PH rat models were established, which were treated by oral administration of TPN171H (5, 25 mg/kg/d) or sildenafil (25 mg/kg/d). The right ventricle systolic pressure (RVSP), right ventricle hypertrophy index (RVHI) and vascular remodeling were measured. The results suggested that TPN171H significantly reduced RVSP and RVHI, and reversed pulmonary vascular remodeling in rats with both models. Furthermore, in in vivo and in vitro research, our data suggested that TPN171H remarkably suppressed cathepsin B-mediated NLRP3 inflammasome activation, which may contribute to its therapeutical function for PH.
WOS关键词VASODILATION ; PATHOGENESIS ; ACTIVATION
资助项目National Natural Science Foundation of China[81773734] ; National Natural Science Foundation of China[81973324] ; Key R&D Programs of Hunan Province[2019SK2241] ; Natural Science Foundation of Hunan Province[2018JJ2544] ; Hunan Young Talent Grant[2020RC3063] ; Hunan Science Foundation[2020JJ5858] ; Wisdom Accumulation and Talent Culti-vation Project of the Third XiangYa Hosipital of Central South University[YX202002]
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000816195500005
出版者ELSEVIER SCIENCE INC
源URL[http://119.78.100.183/handle/2S10ELR8/301735]  
专题新药研究国家重点实验室
通讯作者Wang, Zhen; Li, Xiaohui
作者单位1.Lingang Lab, Shanghai 201602, Peoples R China
2.Vigonvita Life Sci Co Ltd, Suzhou, Peoples R China
3.Cent South Univ, Xiangya Nursing Sch, Changsha 410013, Hunan, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
5.Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Med Chem, Changsha 410013, Hunan, Peoples R China
6.Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410013, Hunan, Peoples R China
推荐引用方式
GB/T 7714		 Zhao, Congke,Hu, Liqing,He, Xiangrong,et al. TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats[J]. VASCULAR PHARMACOLOGY,2022,145:11.
APA Zhao, Congke.,Hu, Liqing.,He, Xiangrong.,Li, Lijun.,Yin, Minghui.,...&Li, Xiaohui.(2022).TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats.VASCULAR PHARMACOLOGY,145,11.
MLA Zhao, Congke,et al."TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats".VASCULAR PHARMACOLOGY 145(2022):11.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。